Zanubrutinib with rituximab for previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation

Zanubrutinib plus rituximab is in clinical development for the treatment of mantle cell lymphoma (MCL) in adults with previously untreated MCL. MCL is a rare type of B-cell non-Hodgkin lymphoma (NHL), a cancer of the lymphatic system. The lymphatic system branches through all parts of the body carrying a liquid called lymph. The lymph contains a high number of white blood cells (lymphocytes) which fight infection. There are two main types of lymphocytes: B-cells and T- cells. MCL affects the B-cells. It develops in the part of the lymph node called the mantle zone. These abnormal B lymphocytes start to collect in the lymph nodes or body organs where they can then form tumours and begin to cause problems within the lymphatic system or other organs. Mantle cell lymphoma is generally considered an aggressive NHL. The exact cause of MCL is unknown. Zanubrutinib offers a safer and more targeted treatment option than older medicines.